On June 22, 2021 Defence Therapeutics reported major breakthrough advances in its pre-clinical research program on its AccuTOX (free AccumTM or AccumTM variants) molecules as potent anti-cancer agents (Press release, Defence Therapeutics, JUN 22, 2021, View Source [SID1234626236]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The AccumTM technology platform is very efficient at enhancing intracellular delivery of proteins of pharmacological interests such as ADCs or vaccine antigens. Defence’s scientific team recently identified a novel function for the use of "free" AccumTM and its recently developed variants as anti-cancer molecules.
"The AccumTM technology platform is displaying multiple targets in its versatility. You can use it with ADCs or any other protein of interest such as vaccine antigens to enhance their intracellular delivery to target cells. We additionally discovered that when delivered without direct linking onto protein, the AccumTM moiety behaves as a toxic "bullet" to cancer cells. Such discovery re-enforces the idea that AccumTM can be exploited for various applications without the need to develop other unrelated molecules." said Sebastien Plouffe, CEO of Defence Therapeutics.
The Defence team engineered a large library of AccumTM variants (over 50 so far). They are currently being testing for their therapeutic efficacy against breast, colon, melanoma and lymphoma cancers. In addition, a new strategy is currently being developed to engineer an "intelligent" Poly-AccuTOX molecule (a chain of various AccuTOX molecules) capable of selectively killing a wide range of cancer cells without collateral side effects.
Global Immunotherapy Market size to reach USD 117 billion by 2026 according to Market Study Report LLC.